The adjunctive use of glucagon-like peptide 1 receptor agonists (GLP-1 RA) as an addition to insulin is increasingly viewed as a method for addressing the rising prevalence of obesity in type 1 diabetes (T1D). Current GLP-1 RA drugs, such as semaglutide and the dual glucagon-insulinotropic peptide (GIP)/GLP-1 tirzepatide...
TheFeel, námestí Smirických, Kostelec n. C. Lesy 28163, Czechia
+31613054419
info@thefeel.org
Copyright © 2023 news.thefeel.org. All Rights Reserved
